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Summary 49 
We examined the effects of fish oil and fenofibrate (FF) on the pancreatic islet 50 
hypertrophy, and on the modification of glucose and lipid metabolic dysfunctions in KK mice 51 
with insulin resistance. The mice were fed one of four diets [25 en% lard/safflower oil (LSO), 52 
25 en% fish oil (FO), or each of these diets plus 0.1 wt% FF (LSO/FF, FO/FF)] for 9 weeks. 53 
FO group and both FF groups had significantly lower final body and adipose tissue weights 54 
than LSO group. Pancreatic islet hypertrophy was observed only in LSO group but not in the 55 
other groups with fish oil or FF. And, it is likely that fish oil has a stronger therapeutic effect 56 
on islet hypertrophy. Plasma adiponectin level was significantly higher in FO group but not 57 
in both FF groups. Expression of hepatic lipogenic enzyme genes such as fatty acid synthase 58 
(FAS) and stearoyl-CoA desaturase-1 (SCD-1) was lower in FO groups with or without FF, 59 
whereas fatty acid oxidation-related mRNAs such as acyl-CoA oxidase (AOX) and 60 
uncoupling protein-2 (UCP-2) were more abundant in FF groups with or without fish oil.  61 
Our results suggest that both fish oil and FF improve pancreatic islet hypertrophy with the 62 
amelioration of insulin resistance. Fish oil enhances insulin sensitivity by increasing plasma 63 
adiponectin; however, the beneficial effect of FF on insulin resistance seems to be 64 
independent of the plasma adiponectin level. These results mean that improvement of glucose 65 
and lipid metabolic dysfuctions in diabetic KK mice are independently approached by fish oil 66 
and FF. 67 
 68 
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Introduction 73 
High fat diets bring about lipid accumulation and de novo lipid synthesis, leading to 74 
obesity and increasing the risk of diabetes, hypertension, hyperlipidemia, metabolic 75 
syndrome, coronary heart disease, and stroke [1-3]. Conversely, diets rich in fish can reduce 76 
plasma triglyceride levels in patients with hyperlipidemia and decrease the risk of coronary 77 
heart disease [4, 5]. Fish oil contains n-3 polyunsaturated fatty acids such as eicosapentaenoic 78 
acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 22:6 n-3), and inhibits lipogenesis and 79 
enhances fatty acid oxidation in the liver [6-8].  80 
Fatty acid and cholesterol synthesis in the liver are mainly regulated by sterol regulatory 81 
element-binding proteins (SREBPs) [9-11]. Fish oil represses maturation of SREBP-1 and 82 
attenuates expression of genes encoding lipogenesis and cholesterol biosynthesis enzymes [8, 83 
12]. On the other hand, fatty acid oxidation and triglyceride hydrolysis are modulated by 84 
peroxisome proliferator-activated receptor α (PPARα) [13-15]. Fish oil activates PPARα and 85 
enhances the expression of genes involved in fatty acid oxidation and triglyceride hydrolysis 86 
such as acyl-CoA oxidase (AOX), lipoprotein lipase, medium-chain acyl-CoA 87 
dehydrogenase, acyl-CoA synthetase and uncoupling protein-2 (UCP-2) [16, 17]. The clinical 88 
anti-hyperlipidemia drug fenofibrate, an agonist of PPARα, decreases triglyceride synthesis 89 
and increases hepatic fatty acid oxidation, reducing the amount of fatty acids available for 90 
triglyceride synthesis [18, 19]. And, fenofibrate treatment lowers plasma concentration of 91 
triglycerides and low density lipoprotein (LDL) cholesterol, and raises the high density 92 
lipoprotein (HDL) cholesterol level [20, 21]. 93 
Our previous study demonstrated that the combination of fish oil and fenofibrate decreased 94 
liver triglycerides and total cholesterol levels, white adipose tissue (WAT) weight, and final 95 
body weight of C57BL/6 mice [22]. And, in KK mice, which develop diabetes with moderate 96 
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obesity, fish oil inhibits the body weight gain and increases insulin sensitivity, whereas 97 
combination of fish oil and fenofibrate inhibits the body weight gain to a greater extent than 98 
does fish oil alone [23]. This study was designed to examine the beneficial effects of fish oil 99 
and fenofibrate on the pancreatic islet hypertrophy, and on the modification of glucose and 100 
lipid metabolic dysfunctions in KK mice with insulin resistance. 101 
 102 
Materials and methods 103 
Animals and diets 104 
Female KK mice were obtained from Tokyo Laboratory Animals Science Co. (Tokyo, 105 
Japan) at 5 weeks of age and were fed a standard rodent diet (CE2; Clea, Tokyo, Japan) for 1 106 
week for acclimatisation. The mice were maintained in a room with controlled temperature 107 
(23 ± 2°C) and humidity (55 ± 10%) with a 12h light/12h dark cycle at the Josai University 108 
Life Science Center. The mice were divided into four dietary groups (n = 5 in each group). 109 
All experimental diets contained 54 en% carbohydrate, 25 en% fat, and 21en% protein and 110 
some were supplemented with 0.1 wt% FF. The composition of experimental diets was 111 
modified on the basis of AIN-93G as described previously [24]. In this study, a 6:4 lard: 112 
safflower oil mixture (LSO) was used as the control dietary fat. The lard (Oriental Yeast, 113 
Tokyo, Japan) contained 44% of oleic acid (18:1 n-9), 24% of palmitic acid (16:0), and 14% 114 
of stearic acid (18:0) as the main fatty acids. Safflower oil (Benibana Foods, Tokyo, Japan) 115 
contained 78% of oleic acid. Fish oil (NOF Corporation, Tokyo, Japan) contained 7% of EPA 116 
(20:5 n-3), 25% of DHA (22:6 n-3), 20% of oleic acid, 18% of palmitic acid, and 5% of 117 
stearic acid. Fenofibate was purchased from Sigma–Aldrich (St. Louis, MO, USA). The mice 118 
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were fed one of four diets [25 en% lard/safflower oil (LSO), 25 en% fish oil (FO), or each of 119 
these diets plus 0.1 wt% FF (LSO/FF, FO/FF)] for 9 weeks. The mice were allowed free 120 
access to water and feed. The details of all the diets are presented in Table 1. The diet was 121 
changed every day, and the residual quantity was recorded. Food intake (g) was represented 122 
on per mouse daily basis. Body weight was recorded once every week. All animal 123 
experiments were performed in accordance with the “Fundamental Guidelines for Proper 124 
Conduct of Animal Experiment and Related Activities in Academic Research Institutions” 125 
(Ministry of Education, Culture, Sports, Science and Technology, Japan, Notice No. 71, 126 
dated June 1, 2006) and approved by the Institutional Animal Care and Use Committee of the 127 
Josai University. 128 
 129 
 130 
Collection of blood and tissue samples 131 
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At the end of the experiment, mice fasted for 3 h were anesthetised with intraperitoneal 132 
injections of pentobarbital sodium (Dainippon Sumitomo Pharma, Osaka, Japan). Blood 133 
samples were drawn from the inferior vena cava and treated with EDTA-2Na, and were 134 
centrifuged (900 ×g, 4°C, 10 min) to separate plasma, which was then frozen at −80°C until 135 
analysis. The liver, white adipose tissue and pancreas were excised. Tissue samples were 136 
weighed, frozen in liquid nitrogen, and stored at −80°C until analysis. 137 
 138 
Measurement of liver and plasma parameters 139 
Hepatic lipids were extracted from approximately 100 mg of liver tissue per mouse by the 140 
method described by Folch et al. [25]. Hepatic triglycerides and total cholesterol, and plasma 141 
triglyceride, total cholesterol and nonesterified fatty acid (NEFA) levels were quantified by 142 
the enzymatic colorimetric method using commercial kits (Wako E-Test kits; Wako Pure 143 
Chemical Industries Ltd., Osaka, Japan). Plasma aspartate transaminase (AST) and alanine 144 
transaminase (ALT) levels were quantified using the Transaminase C-ⅡTest kit (Wako Pure 145 
Chemical Industries Ltd, Osaka, Japan). Plasma insulin (the mouse Insulin kit) and leptin (the 146 
mouse Leptin kit) levels were quantified by the enzyme-linked immunosorbent assay 147 
(ELISA) using commercial kits (Morinaga Institute of Biological Science, Tokyo, Japan). The 148 
plasma adiponectin level was measured using the mouse/rat Adiponectin ELISA kit (Otsuka 149 
Pharmaceutical, Tokyo, Japan). Insulin resistance was assessed using the homeostasis model 150 
of assessment-insulin resistance [HOMA-IR, fasting insulin (μU/mL) × fasting glucose 151 
(mmol/L) / 22.5]. 152 
 153 
Morphological analysis of the liver and pancreas  154 
Liver and pancreatic tissue samples were collected from 4 to 5 mice in each group and 155 
fixed in 10% neutral buffered formalin (Wako Pure Chemical Industries Ltd, Osaka, Japan). 156 
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The tissue samples were then embedded in paraffin, cut into sections, and stained with 157 
haematoxylin and eosin (H&E) for morphological examination. In addition, the pancreatic 158 
sections were stained with insulin and glucagon antibodies (Takara Bio Inc., Shiga, Japan) for 159 
immunohistochemical analysis of islet structure by Kotobiken Medical Laboratories, Inc. 160 
(Tokyo, Japan). The core of the pancreatic islet consists of insulin-positive beta cells 161 
surrounded by glucagon-positive alpha cells (arrow). 162 
 163 
Measurement of mRNA levels by real-time PCR 164 
Portion of liver tissue was homogenised using the TRIzol Reagent (Invitrogen, Carlsbad, 165 
CA, USA), and total RNA was isolated according to the manufacturer’s protocol. The 166 
quantity and purity of total RNA were carefully verified on a spectrophotometer at A260 and 167 
A280. mRNA amplification was performed using a QuantiTect SYBR Green Real-time PCR 168 
kit (Qiagen, Hilden, Germany), and relative mRNA expression levels were quantified by RT-169 
PCR from the cycle number (Ct) for threshold signal detection on an ABI Prism 7500 170 
Sequence Detection System (Applied Biosystems, Foster City, CA, USA). The thermal 171 
cycling conditions were as follows: reverse transcription at 50°C for 30 min, PCR initial 172 
activation at 95°C for 15 min, 40 cycles of denaturation at 94°C for 15 s, annealing at the 173 
optimum temperature of each primer for 30 s, and extension at 72°C for 1 min. A 174 
housekeeping transcript, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), was used as 175 
an endogenous control gene. The details of all PCR primers used are shown in Table 2. 176 
Results were expressed as the ratio of the obtained value to that of LSO group.  177 
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 179 
Statistical analysis 180 
Values are presented as mean ± SD. Statistical analysis of most data was conducted using 181 
two-way analysis of variance (ANOVA), followed by the Tukey–Kramer test (Statview 5.0; 182 
SAS Institute Inc., USA). P<0.05 was considered significantly different. Statistical analysis 183 
of the data for pancreas morphology and insulin positive area in islets was conducted one-184 
way analysis of variance (ANOVA), followed by the Tukey–Kramer test. Groups sharing 185 
different letters significantly different. 186 
 187 
Results 188 
Body and tissue weights 189 
The energy intakes (kcal/mouse/day) were lower tendency in FO and both FF groups. Final 190 
body weight and parametrial WAT weight were lower in FO and both FF groups than in LSO 191 
group (Table 3, final body weight: FO, P = 0.0678; FF, P < 0.01; FO×FF, P < 0.01, 192 
parametrial WAT weight: FO, P < 0.05; FF, P < 0.01; FO×FF, P < 0.01). Body weight was 193 
lower in FO and FO/FF groups than in LSO group as early as 3 weeks since the initiation of 194 
the experimental diets (Fig. 1A).   195 
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Liver weight was decreased in FO group and increased in both FF groups compared to the 196 
other groups (Table 3: FO, P < 0.05; FF, P < 0.01; FO×FF, P < 0.01). There was no main 197 
effect of FF or FO×FF interaction, but there was a main effect of FO in the plasma aspartate 198 
transaminase (AST) levels. And, there was no main effect of FO or FO×FF interaction, but 199 
there was a main effect of FF in the alanine transaminase (ALT) levels (Table 3). 200 
 201 
 202 
 203 
Plasma biochemical markers   204 
As shown in Table 4, although no differences were observed in blood glucose levels by fish 205 
oil or fenofibrate (FF), plasma insulin and HOMA-IR levels were significantly lower in FO 206 
and both FF groups than in LSO group. There was a main effect of FO and FF and FO×FF 207 
interaction in the plasma insulin and HOMA-IR levels. Plasma adiponectin level was 208 
significantly higher in FO group compare with the other groups, showing a main effect of FO 209 
and FO×FF interaction, but no main effect of FF. However, plasma leptin levels did not 210 
change among the groups. 211 
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No significant differences in plasma triglyceride levels were observed between all groups. 212 
Plasma total cholesterol levels were lower in FO and FO/FF groups and were higher in 213 
LSO/FF group than in LSO group. There was a main effect of FO and FF, but no main effect 214 
of FO×FF interaction. Plasma NEFA levels were also significantly lower in FO and both FF 215 
groups than in LSO group (Table 4: FO, P < 0.01; FF, P < 0.01; FO×FF, P = 0.0561).  216 
 217 
 218 
 219 
Liver morphology and hepatic lipids  220 
To determine the effects of fish oil and FF on liver fat accumulation, liver tissue samples 221 
were compared using morphology analysis. Liver tissue in LSO group showed numerous fat 222 
droplets throughout the hepatocyte, whereas no fat droplets were detected in the hepatocytes 223 
of FO and both FF groups (Fig. 1B). Hepatic triglyceride and total cholesterol levels were 224 
significantly lower in FO and both FF groups than in LSO group. There was a main effect of 225 
FO and FF and FO×FF interaction in the hepatic triglyceride and total cholesterol levels 226 
(Fig. 1C and D). 227 
 228 
12 
 
 Pancreas morphology and insulin positive area in islets 229 
We examined whether fish oil and FF inhibit pancreatic islet hypertrophy. Haematoxylin 230 
and eosin (H&E) staining revealed a markedly greater islet size in LSO group than in FO and 231 
both FF groups (Fig. 2A). Statistical analysis of the data for pancreas morphology and insulin 232 
positive area in islets was conducted one-way ANOVA, because the number of islets among 233 
groups is too different to compare by two-way ANOVA. Pancreatic islets area was 234 
significantly lower in FO and FO/FF groups than in LSO group (Fig. 2A and D). Also, islet 235 
density (islet number /section) results were similar trends (15.3 ± 3.8, 7.3 ± 3.2, 4.8 ± 2.2 and 236 
4.8 ± 1.3 in LSO, FO, LSO/FF and FO/FF, respectively). Insulin positive area in islets was 237 
significantly higher in FO and both FF groups than in LSO group (Fig. 2B and E). However, 238 
glucagon positive area did not differ significantly among the groups (Fig. 2C and F).   239 
 240 
Hepatic expression of genes involved in lipid metabolism 241 
To examine the effects of fish oil and FF on lipid metabolism in the liver, hepatic 242 
expression of mRNA encoding enzymes involved in lipid metabolism was measured. Only 243 
minor differences were observed in SREBP-1c mRNA levels among the groups. However, 244 
the mRNA levels of insulin induced gene 1 (Insig-1), stearoyl-CoA desaturase 1 (SCD-1) and 245 
fatty acid synthase (FAS) tended to be greatly lower in both FO groups, with or without FF. 246 
There was a main effect of FO, but no main effect of FF and FO×FF interaction in the 247 
mRNA levels of Insig-1, SCD-1 and FAS. The mRNA levels of microsomal triglyceride 248 
transfer protein were significantly higher in both FF groups than in FF-free groups, showing a 249 
main effect of FO and FF, but no main effect of FO×FF interaction (Fig. 3). 250 
The mRNA levels of AOX and UCP-2, which are related to fatty acid oxidation and heat 251 
production, respectively, were significantly higher in both FF groups. There was a main effect 252 
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of FF, but no main effect of FO and FO×FF interaction in the mRNA levels of AOX and 253 
UCP-2 (Fig. 4).  254 
 255 
Discussion 256 
In this study, we evaluated the effects of fish oil and FF on the pancreatic islet hypertrophy 257 
and observed the modification of glucose and lipid dysfunction in KK mice with insulin 258 
resistance.  259 
The diet containing fish oil significantly decreased final body weight and parametrial WAT 260 
weight in KK mice, which correlates with our previous results [23, 26].  261 
FF treatment in the C57BL/6 mice has been resulted in liver weight increase that is caused 262 
by a peroxisome proliferation [27, 28]. In the present study also, the 0.1% FF treatment in the 263 
female KK mice increased the liver weights. 264 
Fish oil consumption reduces the risk of developing a cardiovascular disease by decreasing 265 
the plasma triglyceride concentration [4, 5]. However, in the present study, the fish oil dose 266 
used in this study did not decrease the plasma triglyceride level. These results are consistent 267 
with our previous studies [23, 26]. We have been also observed that plasma triglyceride levels 268 
were markedly decreased in female KK mice fed 50 en% fish oil diet (data not shown). It 269 
appears that 25 en% fish oil is not sufficient to decrease plasma triglyceride level caused by 270 
the obese state of female KK mice.  271 
Fish oil can induce AOX and UCP-2 mRNA expression through PPARα activation [16, 272 
17]. In the present study, fish oil cannot induce AOX and UCP-2 mRNA expression in the 273 
liver, perhaps because 25 en% fish oil are insufficient for the induction of fatty acid β-274 
oxidation. In contrast, 0.1% FF supplementation induced fatty acid oxidation through an 275 
increase in AOX and UCP-2 mRNA expression.  276 
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FF is known as an agonist of PPARα; it induces fatty acid β-oxidation and lowers hepatic 277 
fat accumulation [20, 23]. The present study shows that FF-supplemented diets decreased 278 
hepatic triglycerides and total cholesterol with or without fish oil. And, FF reduced both final 279 
body weight and fat mass as well as plasma insulin levels. On the other hand, other studies 280 
have shown that FF increases hepatic peroxisome proliferation and liver weight, resulting in 281 
elevated AST and ALT levels [29, 30]. In the present study, although liver weights were 282 
increased in both FF groups, and AST and ALT levels remained within the normal range. 283 
These data suggest that 0.1% FF is sufficient for amelioration of genetic abnormalities in 284 
lipid and glucose metabolism (regardless of the dietary fat source) without the risk of liver 285 
damage. 286 
The basal plasma insulin level is markedly higher in KK mice (2–3 pmol/L) than in 287 
C57BL/6 mice (0.2–0.3 pmol/L), and obesity-prone KK mice develop hyperinsulinemia [23, 288 
31]. In the present study, the plasma insulin level and the HOMA-IR index were extreamly 289 
high in LSO group (fasting insulin 1.5 pmol/L, HOMA-IR 101). And, fish oil and/or FF 290 
markedly decreased the plasma insulin level and HOMA-IR similar to those of non-obese, 291 
non-diabetic C57BL/6 mice. Thus, we suggest that 25 en% fish oil and/or 0.1 wt% FF are 292 
sufficient to protect obesity- and diabetes- prone KK mice from insulin resistance. 293 
Many studies have linked obesity and insulin resistance with hypertrophy and hyperplasia 294 
of pancreatic islet cells [32, 33]. According to our results, pancreatic islet hypertrophy and 295 
islet density were markedly suppressed, and, insulin positive area was significantly increased 296 
by both fish oil and FF. However, it is likely that fish oil has a stronger therapeutic effect on 297 
islet hypertrophy. Further research is required to clarify the therapeutic effects of fish oil and 298 
FF on pancreatic islet hypertrophy and insulin resistance. 299 
Adiponectin released from adipose cells inhibits gluconeogenesis and increases glucose 300 
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uptake and fatty acid oxidation, resulting in enhanced insulin sensitivity [34, 35]. In the 301 
present study, plasma adiponectin levels were significantly higher in FO group but not in any 302 
FF-treated group. This result indicates that fish oil enhance insulin sensitivity by increasing 303 
plasma adiponectin; however, the beneficial effects of FF on body weight and insulin 304 
resistance are independent of the plasma adiponectin level. These results suggest that there is 305 
a diversity of relationships between the plasma adiponectin levels and insulin resistance. 306 
 307 
Conclusions 308 
Our results suggest that fish oil and FF improve pancreatic islet hypertrophy with the 309 
amelioration of insulin resistance, and positively modulate glucose and lipid metabolism in 310 
obesity and diabetes female KK mice. And, these good effects of fish oil and FF may be via a 311 
different way. 312 
 313 
Abbreviations 314 
ACC, acetyl-CoA carboxylase; ALT, alanine aminotransferase; AST, aspartate 315 
aminotransferase; AOX, acyl-CoA oxidase; DHA, docosahexaenoic acid; EPA, 316 
eicosapentaenoic acid; FAS, fatty acid synthase; FF, fenofibrate; FO, fish oil; H&E, 317 
haematoxylin eosin; HOMA-IR, homeostasis model assessment for insulin resistance; PPAR, 318 
peroxisome proliferator-activated receptor; SCD, stearoyl-CoA desaturase; SREBPs, sterol 319 
regulatory element-binding proteins; UCP, uncoupling protein; WAT, white adipose tissue. 320 
 321 
Acknowledgements 322 
We would like to thank Itaru Kondo and Misato Honda for their assistance and NOF 323 
Corporation (Tokyo, Japan) for providing fish oil.  324 
16 
 
 325 
Conflict of interest 326 
 The authors have nothing to declare. 327 
References 328 
[1] Lawrence GD. Dietary fats and health: dietary recommendations in the context of scientific 329 
evidence. Adv Nutr 2013; 4: 294-302. 330 
[2] Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular 331 
disease. Clin Biochem 2009; 42: 1331-46. 332 
[3] Wang CY, Liao JK. A mouse model of diet-induced obesity and insulin resistance. Methods 333 
Mol Biol 2012; 821: 421-33. 334 
[4] Iso H, Kobayashi M, Ishihara J, Sasaki S, Okada K, Kita Y, et al. Intake of fish and n3 335 
fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health 336 
Center-Based (JPHC) Study Cohort I. Circulation 2006; 113: 195-202. 337 
[5] Flachs P, Rossmeisl M, Bryhn M, Kopecky J. Cellular and molecular effects of n-3 338 
polyunsaturated fatty acids on adipose tissue biology and metabolism. Clin Sci 2009; 116: 1-339 
16. 340 
[6] Jump DB. N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr 341 
Opin Lipidol 2008; 19: 242-7. 342 
[7] Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty 343 
acids. Am J Cardiol 2006; 98: 27i-33i. 344 
[8] Nakatani T, Kim H, Kaburagi Y, Yasuda K, Ezaki O. A low fish oil inhibits SREBP-1 345 
proteolytic cascade, while a high-fish-oil feeding decreases SREBP-1 mRNA in mice liver: 346 
relationship to anti-obesity. J Lipid Res 2003; 44: 369-79. 347 
[9] Amemiya-Kudo M, Shimano H, Hasty AH, Yahagi N, Yoshikawa T, Matsuzaka T, et al. 348 
17 
 
Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of 349 
lipogenic and cholesterogenic genes. J Lipid Res 2002; 43: 1220-35. 350 
[10] Brown MS, Goldstein JL. The SREBP pathway regulation of cholesterol metabolism by 351 
proteolysis of a membrane-bound transcription factor. Cell 1997; 89: 331-40. 352 
[11] Horton JD, Goldstein JL, Brown MS. SREBPs activators of the complete program of 353 
cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-31. 354 
[12] Zhu H, Fan C, Xu F, Tian C, Zhang F, Qi K. Dietary fish oil n-3 polyunsaturated fatty 355 
acids and alpha-linolenic acid differently affect brain accretion of docosahexaenoic acid and 356 
expression of desaturases and sterol regulatory element-binding protein 1 in mice. J Nutr 357 
Biochem 2010; 21: 954-60. 358 
[13] Morise A, Thomas C, Landrier JF, Besnard P, Hermier D. Hepatic lipid metabolism 359 
response to dietary fatty acids is differently modulated by PPARalpha in male and female 360 
mice. Eur J Nutr 2009; 48: 465-73. 361 
[14] Issemann I, Green S. Activation of a member of the steroid hormone receptor 362 
superfamily by peroxisome proliferators. Nature 1990; 347: 645-50. 363 
[15] Schoonjans K, Staels B, Auwerx, J. The peroxisome proliferator activated receptors 364 
(PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim 365 
Biophys Acta 1996; 1302: 93-109. 366 
[16] Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, et al. Fatty acids, 367 
eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-368 
activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997; 11: 369 
779-91. 370 
[17] Kim H, Takahashi M, Ezaki O. Fish oil feeding decreases mature sterol regulatory 371 
element-binding protein 1 (SREBP-1) by down-regulation of SREBP-1c mRNA in mouse 372 
liver. A possible mechanism for down-regulation of lipogenic enzyme mRNAs. J Biol Chem 373 
18 
 
1999; 274: 25892-8. 374 
[18] Seo YS, Kim JH, Jo NY, Choi KM, Baik SH, Park JJ, et al. PPAR agonists treatment is 375 
effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid 376 
metabolic enzymes. J Gastroenterol Hepatol 2008; 23: 102-9. 377 
[19] Jeong S, Han M, Lee H, Kim M, Kim J, Nicol CJ, et al. Effects of fenofibrate on high-fat 378 
diet-induced body weight gain and adiposity in female C57BL/6J mice. Metabolism 2004; 379 
53: 1284-9. 380 
[20] Ikewaki K, Tohyama J, Nakata Y, Wakikawa T, Kido T, Mochizuki S. Fenofibrate 381 
effectively reduces remnants, and small dense LDL, and increases HDL particle number in 382 
hypertriglyceridemic men - a nuclear magnetic resonance study. J Atheroscler Thromb 2004; 383 
11: 278-85. 384 
[21] Tokuno A, Hirano T, Hayashi T, Mori Y, Yamamoto T, Nagashima M, et al. The effects 385 
of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients 386 
with type 2 diabetes. J Atheroscler Thromb 2007; 14: 128-32. 387 
[22] Arai T, Kim H, Chiba H, Matsumoto A. Interaction of fenofibrate and fish oil in relation 388 
to lipid metabolism in mice. J Atheroscler Thromb 2009; 16: 283–91. 389 
[23] Arai T, Kim H, Chiba H, Matsumoto A. Anti-obesity effect of fish oil and fish oil-390 
fenofibrate combination in female KK mice. J Atheroscler Thromb 2009; 16: 674-83. 391 
[24] Ikemoto S, Takahashi M, Tsunoda N, Maruyama K, Itakura H, Ezaki O. High fat diet-392 
induced hyperglycemia and obesity in mice: differential effects of dietary oils. Metabolism 393 
1996; 45: 1539-46. 394 
[25] Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification 395 
of total lipids from animal tissues. J Biol Chem 1957; 226: 497-509. 396 
[26] Arai T, Kim H, Hirako S, Nakasatomi M, Chiba H, Matsumoto A. Effects of dietary fat 397 
energy restriction and fish oil feeding on hepatic metabolic abnormalities and insulin 398 
19 
 
resistance in KK mice with high-fat diet-induced obesity. J Nutr Biochem 2013; 24: 267-73. 399 
[27] Lu Y, Boekschoten MV, Wopereis S, Müller M, Kersten S. Comparative transcriptomic 400 
and metabolomic analysis of fenofibrate and fish oil treatments in mice. Physiol Genomics 401 
2011; 43: 1307-18. 402 
[28] Gao M, Bu L, Ma Y, Liu D. Concurrent activation of liver X receptor and peroxisome 403 
proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced 404 
obese mice. PLOS ONE 2013; 8: 1-11. 405 
[29] Oosterveer MH, Grefhorst A, van Dijk TH, Havinga R, Staels B, Kuipers F, et al. 406 
Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in 407 
mice. J Biol Chem 2009; 284: 34036-44. 408 
[30] Kobayashi A, Suzuki Y, Kuno H, Sugai S, Sakakibara H, Shimoi K. Effects of 409 
fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene 410 
expression in rats. J Toxicol Sci 2009; 34: 377-87. 411 
[31] Thakker GD, Frangogiannis NG, Bujak M, Zymek P, Gaubatz JW, Reddy AK, et al.  412 
Effects of diet-induced obesity on inflammation and remodeling after myocardial infarction. 413 
Am J Physiol Heart Circ Physiol 2006; 291: H2504- 14. 414 
[32] Kawashima S, Matsuoka T, Kaneto H, Tochino Y, Kato K, Yamamoto K, et al.: Effect of 415 
alogliptin, pioglitazone, increased islet volume but unchanged islet number in ob/ob mice. 416 
Biochem Biophys Res Commun 2011; 404: 534-40.  417 
[33] Kargar C, Ktorza A: Anatomical versus functional β-cell mass in experimental diabetes. 418 
Diabetes Obes Metab 2008; 10: 43-53.  419 
[34] Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to 420 
biomarker of the metabolic syndrome. J Intern Med 2005; 257: 167-75. 421 
[35] Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, , et al. Adiponectin 422 
stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein 423 
20 
 
kinase. Nat Med 2002; 8: 1288-95. 424 
 21 
 
Figure legends 425 
 426 
Figure 1  427 
Effects of fish oil and fenofibrate on body weight, hepatic fat accumulation, hepatic 428 
triglyceride and total cholesterol levels of diabetic KK mice. LSO, lard/safflower oil; FO, fish 429 
oil; FF, fenofibrate. Mice were fed the indicated experimental diets for 9 weeks. (A) Body 430 
weights, (B) liver morphology, (C) hepatic triglyceride and (D) hepatic total cholesterol. 431 
Body weights were plotted until 9 weeks. Liver tissues from 4 to 5 mice in each group were 432 
embedded in paraffin, stained with H&E, and examined under a microscope (400×). Values 433 
represent mean ± S.D. (n = 4-5).Two-way ANOVA results are shown at the bottom of the 434 
each figure. NS, not significant. 435 
 436 
Figure 2 437 
Effects of fish oil and fenofibrate on morphology of pancreatic islet in diabetic KK mice. 438 
LSO, lard/safflower oil; FO, fish oil; FF, fenofibrate. Mice were fed the indicated 439 
experimental diets for 9 weeks. (A) Islet stained with H&E, (B) islet marked with insulin 440 
antibodies, (C) islet marked with glucagon antibodies, (D) islets area, (E) insulin positive area 441 
and (F) glucagon positive area. Pancreatic tissues from 4 to 5 mice in each group were 442 
embedded in paraffin, and stained with H&E, insulin and glucagon antibodies. Then, the 443 
tissue section examined under a microscope (400×). The core of the pancreatic islet consists 444 
of insulin-positive beta cells surrounded by glucagon-positive alpha cells (arrow). Insulin and 445 
glucagon positive areas were represented as a percentage of the islets areas. (D, E) The data 446 
were compared by one-way ANOVA, followed by the Tukey-Kramer test. Groups sharing 447 
different letters significantly different (P < 0.05).  448 
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 449 
Figure 3 450 
Effects of fish oil and fenofibrate on hepatic mRNA expression of genes involved in fatty 451 
acid synthesis in diabetic KK mice. LSO, lard/safflower oil; FO, fish oil; FF, fenofibrate. Mice 452 
were fed the indicated experimental diets for 9 weeks. Panels show mRNA expression levels 453 
of (A) SREBP-1c, (B) Insig-1, (C) FAS, (D) SCD-1 and (E) MTP. mRNA levels were 454 
determined by real-time quantitative PCR. Results are expressed as the ratio of the obtained 455 
value to that of LSO group. Values represent mean ± S.D. (n = 4-5). Two-way ANOVA results 456 
are shown at the bottom of the each figure. NS, not significant. 457 
 458 
Figure 4 459 
Effects of fish oil and fenofibrate on hepatic mRNA expression of genes involved in fatty 460 
acid oxidation and cholesterol metabolism in diabetic KK mice. LSO, lard/safflower oil; FO, 461 
fish oil; FF, fenofibrate. Mice were fed the indicated experimental diets for 9 weeks. Panels 462 
show mRNA expression levels of (A) AOX and (B) UCP-2. mRNA levels were determined by 463 
real-time quantitative PCR. Results are expressed as the ratio of the obtained value to that of 464 
LSO group. Values represent mean ± S.D. (n = 4-5). Two-way ANOVA results are shown at 465 
the bottom of the each figure. NS, not significant. 466 
 467 
 468 
 469 
 470 
 471 
 472 
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Table 1   Composition of the experimental diets
Ingredient (g) LSO FO LSO/FF FO /FF
Lard 4.20 4.20 
Safflower oil 6.30 6.30 
Fish oil 10.50 10.50 
Casein 21.00 21.00 21.00 21.00 
Sucrose 10.50 10.50 10.50 10.50 
β-Starch 47.45 47.45 47.45 47.45 
Vitamin mixa 1.31 1.31 1.31 1.31 
Mineral mixa 3.68 3.68 3.68 3.68 
Cellulose powder 5.25 5.25 5.25 5.25 
L-Cystine 0.32 0.32 0.32 0.32 
t-Butylhydroquinone 0.0021 0.0021 0.0021 0.0021
Fenofibrate 0.1 0.1
Total (g) 100.0 100.0 100.1 100.1
Total energy (kcal/100g) 386.6 385.8 386.4 385.6 
Fat energy (kcal/100g) 97.4 96.6 97.4 96.5
Fat energy( % ) 25.2 25.0 25 .2 25 .0
LSO, lard/safflower oil; FO, fish oil; FF, fenofibrate. a Vitamin mix and mineral mix were prepared according to the American 
Institute of Nutrition (AIN)-93G formulation. Vitamin mix included 0.25% sucrose for chorine bitartrate supplementation.
Table 2   Primer  sequences for real-time PCR amplification
Genes Forward primer (5’-3’) Reverse primer (3’-5’)
SREBP-1c GGAGCCATGGATTGCACATT GGCCCGGGAAGTCACTGT
Insig-1 TCACAGTGACTGAGCTTCAGCA TCATCTTCATCACACCCAGGAC
FAS TCACCACTGTGGGCTCTGCAGAGAAGCGAG TGTCATTGGCCTCCTCAAAAAGGGCGTCCA
SCD-1 CCGGAGACCCCTTAGATCGA TAGCCTGTAAAAGATTTCTGCAAACC
MTP GCTCCCTCAGCTGGTGGAT CAGGATGGCTTCTAGCGAGTCT
AOX TCAACAGCCCAACTGTGACTTCCATTA TCAGGTAGCCATTATCCATCTCTTCA
UCP-2 GTTCCTCTGTCTCGTCTTGC GGCCTTGAAACCAACCA
GAPDH TGTGTCCGTCGTGGATCTGA CCTGCTTCACCACCTTCTTGAT
SREBP-1c, sterol regulatory element binding  protein 1; Insig-1, insulin induced gene 1; FAS, fatty acid synthase; SCD-1, 
stearoyl-CoA desaturase 1; MTP, microsomal triglyceride protein; AOX, acyl-coenzyme A oxidase; UCP-2, uncoupling 
protein 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Groups
Final body weight (g)
Initial body  weight (g) 24.7±1.4 24.6±0.9 24.7±1.3 24.6±0.7
46.0±4.7 39.2±2.7 37.7±1.8 39.3±1.6
Liver weight (g) 2.88±0.93 1.50±0.24 3.30±0.16 3.53±0.12
4.62±0.67 3.34±0.43 2.78±0.49 2.88±0.31
0.50±0.07 0.53±0.22 0.33±0.03 0.41±0.10
Table 3   Effects of fish oil and fenofibrate on body weights, tissue weights, and liver function makers of diabetic KK
mice
FO/FFLSO/FFLSO FO
LSO, lard/safflower oil; FO, fish oil; FF, fenofibrate; WAT, white adipose tissue; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase. aDaily food energy intake calculated on the basis of total energy for each experimental diet. Values represent the mean 
± S.D. (n=4-5). NS, not significant.
Parametrial WAT weight (g)
Perirenal WAT weight (g)
AST activity (IU/L) 20.9±5.8 35.6±13.5 19.6±7.4 35.1±7.9
ALT activity (IU/L) 6.7±2.1 6.2±3.9 10.9±5.7 11.3±2.2
Body and tissue weights
Liver function makers
Food intake (kcal/mouse/day) a 17.0 15.3 16.4 15.4
Two-way ANOVA P-values
FO FF FO×FF
NSNS NS
<0.010.0678 <0.01
NS<0.01 NS
<0.05NS NS
<0.01<0.05 <0.01
<0.05NS NS
<0.01<0.05 <0.01
-- -
Table 4   Effects of fish oil and fenofibrate on glucose homeostasis makers and plasma biochemical makers of diabetic 
KK mice
LSO, lard/safflower oil; FO, fish oil; FF, fenofibrate; HOMA-IR, homeostasis model assessment for insulin resistance; NEFA, non-esterified 
fatty acid. Values represent the mean ± S.D. (n=4-5). NS, not significant.
Blood glucose (mmol/L)
Plasma insulin (pmol/L)
Adiponectin (μg/mL)
1.52±0.62 0.47±0.34 0.31±0.22 0.18±0.06
17.4±4.4 31.1±7.8 21.6±1.5 21.8±2.6
Leptin (ng/mL) 28.5±1.4 28.0±2.7 22.4±7.4 27.0±3.0
HOMA-IR
10.6±2.6 10.6±2.5 13.1±1.8 11.5±1.3
101±25 30±20 29±24 14±6
Total cholesterol (mmol/L)
NEFA (mmol/L)
Triglyceride (mmol/L) 1.29±0.53 1.25±0.13 1.26±0.18 0.87±0.25
4.56±0.81 1.94±0.09 5.35±0.45 3.54±0.37
0.92±0.30 0.31±0.09 0.52±0.08 0.22±0.08
Glucose homeostasis makers
Plasma biochemical makers
Groups
FO/FFLSO/FFLSO FO
Two-way ANOVA P-values
FO FF FO×FF
NSNS NS
NS<0.01 <0.01
NSNS NS
<0.01<0.01 NS
NSNS NS
<0.01<0.01 <0.05
<0.01<0.01 <0.01
<0.01<0.01 0.0561
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